Zachary Yochum, MD/PhD
Clinical Fellow
Biography
Research & Publications
News
Selected Publications
- Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancerYochum Z, Cades J, Wang H, Chatterjee S, Simons B, O’Brien J, Khetarpal S, Lemtiri-Chlieh G, Myers K, Huang E, Rudin C, Tran P, Burns T. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene 2018, 38: 656-670. PMID: 30171258, PMCID: PMC6358506, DOI: 10.1038/s41388-018-0482-y.
- TWIST1 regulation of circRNA: a novel mechanism to promote epithelial-mesenchymal transition in hepatocellular carcinomaYochum Z, Burns T. TWIST1 regulation of circRNA: a novel mechanism to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Non-coding RNA Investigation 2018, 2: 71-71. PMID: 30734026, PMCID: PMC6363344, DOI: 10.21037/ncri.2018.12.01.
- Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancerYochum Z, Stabile L. Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer. Translational Lung Cancer Research 2020, 9: 1599-1605. PMID: 32953532, PMCID: PMC7481617, DOI: 10.21037/tlcr-20-617.
- Alternative splicing of HER2: a novel mediator of EGFR TKI resistanceYochum Z, Villaruz L. Alternative splicing of HER2: a novel mediator of EGFR TKI resistance. Translational Lung Cancer Research 2020, 9: 1606-1612. PMID: 32953533, PMCID: PMC7481647, DOI: 10.21037/tlcr-20-618.
- High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcomeDelgado E, Boisen M, Laskey R, Chen R, Song C, Sallit J, Yochum Z, Andersen C, Sikora M, Wagner J, Safe S, Elishaev E, Lee A, Edwards R, Haluska P, Tseng G, Schurdak M, Oesterreich S. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecologic Oncology 2016, 141: 348-356. PMID: 26946093, PMCID: PMC5154956, DOI: 10.1016/j.ygyno.2016.02.030.
- Paradoxical functions of ZEB1 in EGFR -mutant lung cancer: tumor suppressor and driver of therapeutic resistanceYochum Z, Socinski M, Burns T. Paradoxical functions of ZEB1 in EGFR -mutant lung cancer: tumor suppressor and driver of therapeutic resistance. Journal Of Thoracic Disease 2016, 8: e1528-e1531. PMID: 28066651, PMCID: PMC5179406, DOI: 10.21037/jtd.2016.11.59.
- A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung CancerYochum Z, Cades J, Mazzacurati L, Neumann N, Khetarpal S, Chatterjee S, Wang H, Attar M, Huang E, Chatley S, Nugent K, Somasundaram A, Engh J, Ewald A, Cho Y, Rudin C, Tran P, Burns T. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Molecular Cancer Research 2017, 15: 1764-1776. PMID: 28851812, PMCID: PMC5712248, DOI: 10.1158/1541-7786.mcr-17-0298.
- TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim ExpressionGodse N, Khan N, Yochum Z, Gomez-Casal R, Kemp C, Shiwarski D, Seethala R, Kulich S, Seshadri M, Burns T, Duvvuri U. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clinical Cancer Research 2017, 23: 7324-7332. PMID: 28899969, PMCID: PMC5898434, DOI: 10.1158/1078-0432.ccr-17-1561.
- P190B RhoGAP Regulates Chromosome Segregation in Cancer CellsHwang M, Peddibhotla S, McHenry P, Chang P, Yochum Z, Park K, Sears J, Vargo-Gogola T. P190B RhoGAP Regulates Chromosome Segregation in Cancer Cells. Cancers 2012, 4: 475-489. PMID: 22582143, PMCID: PMC3348653, DOI: 10.3390/cancers4020475.
- TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancerKumar V, Yochum Z, Devadassan P, Huang E, Miller E, Baruwal R, Rumde P, GaitherDavis A, Stabile L, Burns T. TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 2024, 1-14. PMID: 38485737, DOI: 10.1038/s41388-024-02987-5.
- The HGF-MET signaling pathway is enriched in LUAC brain metastases.Velez M, Yochum Z, Chandran U, Chakka A, Bhattacharya S, Somasundaram A, LaFramboise W, Wallweber G, Ravanera R, Kurland B, Dacic S, Stabile L, Burns T. The HGF-MET signaling pathway is enriched in LUAC brain metastases. Journal Of Clinical Oncology 2019, 37: e20597-e20597. DOI: 10.1200/jco.2019.37.15_suppl.e20597.